This Ilaris market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed in the historical period can be attributed to several factors, including an increase in autoimmune disorders, a rise in clinical trials, greater awareness of precision medicine, and an expanding healthcare workforce, along with the growth of medical tourism.
Market growth during the forecast period driven by the increasing prevalence of inflammatory bowel disease and various other inflammatory disorders, the growing use of targeted therapies, an aging population, and the rising incidence of chronic diseases. Key trends during the forecast period include advancements in technology, personalized medicine, combination therapies, digital health tools, and the expansion of telemedicine.
The growing prevalence of inflammatory diseases is expected to drive the expansion of the ilaris market. Inflammatory diseases occur when the immune system triggers inflammation in tissues, leading to pain, swelling, and potential damage. Factors such as aging populations, environmental triggers, lifestyle changes, genetic predispositions, and the rising incidence of autoimmune disorders contribute to the increasing prevalence of these diseases. Ilaris is used to treat inflammatory conditions such as cryopyrin-associated periodic syndromes (CAPS) by inhibiting interleukin-1β, thereby reducing inflammation and related symptoms. For example, in September 2023, a report from the National Library of Medicine indicated that the incidence of inflammatory bowel disease (IBD) in Canada was 30 per 100,000, with an expected annual increase of 0.58%, reaching 32.1 per 100,000 by 2035. This rise in inflammatory diseases is driving the growth of the ilaris market.
The increasing geriatric population is expected to contribute to the growth of the ilaris market. This demographic, comprising individuals aged 65 and older, is expanding due to advancements in healthcare and improved living standards that extend life expectancy, coupled with declining birth rates in many regions. Ilaris plays a critical role in treating chronic inflammatory conditions, such as gout flares and autoinflammatory diseases, particularly in older adults who may struggle with conventional therapies due to age-related health challenges. The World Health Organization forecasts that the global population aged 60 and older will grow from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. The number of individuals aged 80 and above is expected to triple, reaching 426 million. This increasing geriatric population is set to drive the ilaris market.
A significant trend in the ilaris market is the development of innovative biologic therapies for treating inflammatory conditions. Biologic therapies use substances derived from living organisms to specifically target immune system components in the treatment of diseases. For instance, in August 2023, Novartis AG announced that the U.S. Food and Drug Administration (FDA) approved Ilaris (canakinumab) for treating gout flares in adults who cannot tolerate NSAIDs, colchicine, or repeated corticosteroid courses, or for whom these treatments are ineffective. This approval marked Ilaris as the first biologic therapy for gout flares, offering a new option for managing this painful condition. Phase 3 clinical trials showed significant reductions in pain intensity and flare recurrence, with no unexpected safety concerns, further supporting the growth of the ilaris market.
The key company operating in the ilaris market is Novartis AG.
North America was the largest region in the ilaris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ilaris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ilaris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Ilaris (canakinumab) is a monoclonal antibody used to treat various inflammatory conditions, including some rare autoinflammatory diseases. It works by blocking interleukin-1 beta (IL-1β), a cytokine that plays a key role in inflammation. Ilaris is approved for treating disorders such as cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and systemic juvenile idiopathic arthritis (SJIA). By reducing inflammation, it helps prevent severe symptoms and complications of these conditions, thereby improving the quality of life for patients who do not respond to conventional therapies.
The primary groups of patients using ilaris include both pediatric and adult populations. Pediatric patients, who are under 18, often require care that is adjusted for their developmental needs. Ilaris is available through hospitals, specialty clinics, online pharmacies, and retail pharmacies, and is prescribed for conditions such as cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, gout, and other inflammatory diseases.
The ilaris market research report is one of a series of new reports that provides ilaris market statistics, including ilaris industry global market size, regional shares, competitors with a ilaris market share, detailed ilaris market segments, market trends and opportunities, and any further data you may need to thrive in the ilaris industry. This ilaris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ilaris market consists of sales of secukinumab, erenumab, and dabrafenib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed in the historical period can be attributed to several factors, including an increase in autoimmune disorders, a rise in clinical trials, greater awareness of precision medicine, and an expanding healthcare workforce, along with the growth of medical tourism.
Market growth during the forecast period driven by the increasing prevalence of inflammatory bowel disease and various other inflammatory disorders, the growing use of targeted therapies, an aging population, and the rising incidence of chronic diseases. Key trends during the forecast period include advancements in technology, personalized medicine, combination therapies, digital health tools, and the expansion of telemedicine.
The growing prevalence of inflammatory diseases is expected to drive the expansion of the ilaris market. Inflammatory diseases occur when the immune system triggers inflammation in tissues, leading to pain, swelling, and potential damage. Factors such as aging populations, environmental triggers, lifestyle changes, genetic predispositions, and the rising incidence of autoimmune disorders contribute to the increasing prevalence of these diseases. Ilaris is used to treat inflammatory conditions such as cryopyrin-associated periodic syndromes (CAPS) by inhibiting interleukin-1β, thereby reducing inflammation and related symptoms. For example, in September 2023, a report from the National Library of Medicine indicated that the incidence of inflammatory bowel disease (IBD) in Canada was 30 per 100,000, with an expected annual increase of 0.58%, reaching 32.1 per 100,000 by 2035. This rise in inflammatory diseases is driving the growth of the ilaris market.
The increasing geriatric population is expected to contribute to the growth of the ilaris market. This demographic, comprising individuals aged 65 and older, is expanding due to advancements in healthcare and improved living standards that extend life expectancy, coupled with declining birth rates in many regions. Ilaris plays a critical role in treating chronic inflammatory conditions, such as gout flares and autoinflammatory diseases, particularly in older adults who may struggle with conventional therapies due to age-related health challenges. The World Health Organization forecasts that the global population aged 60 and older will grow from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. The number of individuals aged 80 and above is expected to triple, reaching 426 million. This increasing geriatric population is set to drive the ilaris market.
A significant trend in the ilaris market is the development of innovative biologic therapies for treating inflammatory conditions. Biologic therapies use substances derived from living organisms to specifically target immune system components in the treatment of diseases. For instance, in August 2023, Novartis AG announced that the U.S. Food and Drug Administration (FDA) approved Ilaris (canakinumab) for treating gout flares in adults who cannot tolerate NSAIDs, colchicine, or repeated corticosteroid courses, or for whom these treatments are ineffective. This approval marked Ilaris as the first biologic therapy for gout flares, offering a new option for managing this painful condition. Phase 3 clinical trials showed significant reductions in pain intensity and flare recurrence, with no unexpected safety concerns, further supporting the growth of the ilaris market.
The key company operating in the ilaris market is Novartis AG.
North America was the largest region in the ilaris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ilaris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ilaris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Ilaris (canakinumab) is a monoclonal antibody used to treat various inflammatory conditions, including some rare autoinflammatory diseases. It works by blocking interleukin-1 beta (IL-1β), a cytokine that plays a key role in inflammation. Ilaris is approved for treating disorders such as cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and systemic juvenile idiopathic arthritis (SJIA). By reducing inflammation, it helps prevent severe symptoms and complications of these conditions, thereby improving the quality of life for patients who do not respond to conventional therapies.
The primary groups of patients using ilaris include both pediatric and adult populations. Pediatric patients, who are under 18, often require care that is adjusted for their developmental needs. Ilaris is available through hospitals, specialty clinics, online pharmacies, and retail pharmacies, and is prescribed for conditions such as cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, gout, and other inflammatory diseases.
The ilaris market research report is one of a series of new reports that provides ilaris market statistics, including ilaris industry global market size, regional shares, competitors with a ilaris market share, detailed ilaris market segments, market trends and opportunities, and any further data you may need to thrive in the ilaris industry. This ilaris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ilaris market consists of sales of secukinumab, erenumab, and dabrafenib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Ilaris Market Characteristics4. Ilaris Market Trends and Strategies5. Ilaris Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Ilaris Pricing Analysis & Forecasts30. Global Ilaris Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Ilaris Market32. Recent Developments in the Ilaris Market
3. Ilaris Market Biologic Drug Characteristics
6. Global Ilaris Growth Analysis and Strategic Analysis Framework
8. Ilaris Market Segmentation
9. Global Ilaris Epidemiology of Clinical Indications
10. Ilaris Market Regional and Country Analysis
11. Asia-Pacific Ilaris Market
12. China Ilaris Market
13. India Ilaris Market
14. Japan Ilaris Market
15. Australia Ilaris Market
16. South Korea Ilaris Market
17. Western Europe Ilaris Market
18. UK Ilaris Market
19. Germany Ilaris Market
20. France Ilaris Market
21. Eastern Europe Ilaris Market
22. North America Ilaris Market
23. USA Ilaris Market
24. Canada Ilaris Market
25. South America Ilaris Market
26. Middle East Ilaris Market
27. Africa Ilaris Market
28. Ilaris Market Competitive Landscape and Company Profiles
29. Global Ilaris Market Pipeline Analysis
33. Ilaris Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Ilaris Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on ilaris market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ilaris? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ilaris market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Patient Demographics: Pediatric Patients; Adult Patients2) by Distribution Channel: Hospitals; Specialty Clinics; Online Pharmacies; Retail Pharmacies
3) by Application: Cryopyrin-Associated Periodic Syndromes; Systemic Juvenile Idiopathic Arthritis; Gout; Other Inflammatory Conditions
Key Companies Mentioned: Novartis AG
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Novartis AG
